PL1983984T3 - Leczenie stwardnienia guzowatego - Google Patents

Leczenie stwardnienia guzowatego

Info

Publication number
PL1983984T3
PL1983984T3 PL07711417T PL07711417T PL1983984T3 PL 1983984 T3 PL1983984 T3 PL 1983984T3 PL 07711417 T PL07711417 T PL 07711417T PL 07711417 T PL07711417 T PL 07711417T PL 1983984 T3 PL1983984 T3 PL 1983984T3
Authority
PL
Poland
Prior art keywords
tuberous sclerosis
sclerosis treatment
treatment
tuberous
sclerosis
Prior art date
Application number
PL07711417T
Other languages
English (en)
Inventor
William Berg
John Benedetto
Ingrid Elmroth
Heidi Lane
David Lebwohl
William Sellers
Michael Stumm
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37944274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1983984(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0602123A external-priority patent/GB0602123D0/en
Priority claimed from GB0603568A external-priority patent/GB0603568D0/en
Priority claimed from GB0604593A external-priority patent/GB0604593D0/en
Priority claimed from GB0605760A external-priority patent/GB0605760D0/en
Priority claimed from GB0609698A external-priority patent/GB0609698D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1983984T3 publication Critical patent/PL1983984T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07711417T 2006-02-02 2007-01-31 Leczenie stwardnienia guzowatego PL1983984T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0602123A GB0602123D0 (en) 2006-02-02 2006-02-02 Organic compounds
GB0603568A GB0603568D0 (en) 2006-02-22 2006-02-22 Organic compounds
GB0604593A GB0604593D0 (en) 2006-03-07 2006-03-07 Organic compounds
GB0605760A GB0605760D0 (en) 2006-03-22 2006-03-22 Organic compounds
GB0609698A GB0609698D0 (en) 2006-05-16 2006-05-16 Organic compounds
EP07711417.1A EP1983984B1 (en) 2006-02-02 2007-01-31 Tuberous sclerosis treatment
PCT/EP2007/000818 WO2007088034A2 (en) 2006-02-02 2007-01-31 Tuberous sclerosis treatment

Publications (1)

Publication Number Publication Date
PL1983984T3 true PL1983984T3 (pl) 2018-08-31

Family

ID=37944274

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07711417T PL1983984T3 (pl) 2006-02-02 2007-01-31 Leczenie stwardnienia guzowatego

Country Status (21)

Country Link
US (1) US20100305150A1 (pl)
EP (2) EP3348265A1 (pl)
JP (2) JP5639743B2 (pl)
KR (2) KR20140016439A (pl)
CN (1) CN104000818B (pl)
AU (1) AU2007211613C1 (pl)
BR (1) BRPI0707684B1 (pl)
CA (1) CA2637255C (pl)
CY (1) CY1120741T1 (pl)
DK (1) DK1983984T3 (pl)
ES (1) ES2672627T3 (pl)
HK (1) HK1251156A1 (pl)
HU (1) HUE037890T2 (pl)
LT (1) LT1983984T (pl)
MX (1) MX339116B (pl)
PL (1) PL1983984T3 (pl)
PT (1) PT1983984T (pl)
RU (1) RU2473343C2 (pl)
SI (1) SI1983984T1 (pl)
TR (1) TR201807065T4 (pl)
WO (1) WO2007088034A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140016439A (ko) 2006-02-02 2014-02-07 노파르티스 아게 결절성 경화증의 치료
US20130225603A1 (en) * 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
JP5652795B2 (ja) * 2011-01-31 2015-01-14 国立大学法人大阪大学 皮膚疾患を処置するための外用薬およびその製造方法
WO2013074583A1 (en) * 2011-11-14 2013-05-23 The Broad Institute, Inc. Treatment and prognosis of lymphangioleiomyomatosis
US9597339B2 (en) 2013-02-01 2017-03-21 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
US9925202B2 (en) 2013-03-04 2018-03-27 Brigham And Women's Hospital, Inc. Treatment of lymphangioleiomyomatosis
LT2976074T (lt) 2013-03-19 2020-03-25 Universitat Pompeu-Fabra Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis
CN106061482A (zh) 2013-10-08 2016-10-26 拉姆医疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
RU2016136348A (ru) 2014-02-11 2018-03-16 Лэм Терапьютикс, Инк. Рапамицин для лечения лимфангиолейомиоматоза
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
CN104490873A (zh) * 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
JP6541124B2 (ja) * 2015-03-23 2019-07-10 国立大学法人大阪大学 びまん性神経線維腫用の外用薬
US20190167649A1 (en) 2016-08-10 2019-06-06 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
AU2020226527A1 (en) 2019-02-20 2021-10-14 AI Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DE69624921T2 (de) * 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
CN1551767A (zh) 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
EP1546369A4 (en) * 2002-08-12 2007-01-17 Univ Michigan DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD
US20050070567A1 (en) * 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
US20040266811A1 (en) * 2002-11-08 2004-12-30 Weinstein David E. Methods for inducing regeneration, remyelination, and hypermyelination of nervous tissue
TW200902047A (en) * 2003-02-14 2009-01-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CA2531454C (en) * 2003-07-08 2011-10-25 Novartis Ag Use of rapamycin and rapamycin derivatives for the treatment of bone loss
EP1648900A4 (en) * 2003-07-11 2010-02-10 Ariad Pharma Inc PHOSPHORUS MACROCYCLES
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
WO2006071966A2 (en) * 2004-12-29 2006-07-06 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1
KR20140016439A (ko) 2006-02-02 2014-02-07 노파르티스 아게 결절성 경화증의 치료

Also Published As

Publication number Publication date
BRPI0707684A8 (pt) 2017-12-26
AU2007211613A1 (en) 2007-08-09
LT1983984T (lt) 2018-06-11
KR20080090493A (ko) 2008-10-08
RU2473343C2 (ru) 2013-01-27
JP2013224298A (ja) 2013-10-31
HUE037890T2 (hu) 2018-09-28
PT1983984T (pt) 2018-06-14
MX339116B (es) 2016-05-12
CY1120741T1 (el) 2019-12-11
JP5639743B2 (ja) 2014-12-10
WO2007088034A2 (en) 2007-08-09
BRPI0707684A2 (pt) 2011-05-10
CA2637255A1 (en) 2007-08-09
JP2009525294A (ja) 2009-07-09
KR20140016439A (ko) 2014-02-07
SI1983984T1 (en) 2018-06-29
BRPI0707684B1 (pt) 2021-10-13
CN104000818B (zh) 2017-11-21
US20100305150A1 (en) 2010-12-02
ES2672627T3 (es) 2018-06-15
CA2637255C (en) 2018-06-12
DK1983984T3 (en) 2018-06-14
TR201807065T4 (tr) 2018-06-21
EP3348265A1 (en) 2018-07-18
EP1983984B1 (en) 2018-03-07
WO2007088034A3 (en) 2007-11-01
EP1983984A2 (en) 2008-10-29
RU2008135131A (ru) 2010-03-10
HK1251156A1 (en) 2019-01-25
AU2007211613C1 (en) 2018-01-04
AU2007211613B2 (en) 2011-04-28
CN104000818A (zh) 2014-08-27

Similar Documents

Publication Publication Date Title
HUE037890T2 (hu) Sclerosis tuberosa kezelése
IL181378A0 (en) Liquid-mixing infusor
GB0606604D0 (en) Treatment apparatus
PL2061385T3 (pl) Urządzenie do zabiegów naczyniowych
IL197818A0 (en) Multiple sclerosis therapy
GB0624874D0 (en) Treatment
GB0718523D0 (en) Agricultural treatment
GB0600692D0 (en) Well treatment
GB0616226D0 (en) Processes
GB0607394D0 (en) Process
GB0600914D0 (en) Process
GB0621527D0 (en) Acne treatment
GB0604874D0 (en) Process
GB2444117B (en) Food treatment
GB0511769D0 (en) Treatment
GB0607952D0 (en) Novel treatment
GB0604233D0 (en) Process
GB0604460D0 (en) Treatment
GB0716608D0 (en) Distortion-tolerant processing
GB0606283D0 (en) Process
GB0608402D0 (en) Thyroid treatment
GB0614058D0 (en) Treatment for multiple sclerosis
GB0602857D0 (en) The treatment of sialorrhoea
GB0609792D0 (en) The treatment of multiple sclerosis
GB2441499B (en) Slimming Spray